KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics
GET POWR RATINGS... FREE!
KALV POWR Grades
- KALV scores best on the Value dimension, with a Value rank ahead of 49.95% of US stocks.
- The strongest trend for KALV is in Stability, which has been heading down over the past 31 weeks.
- KALV ranks lowest in Momentum; there it ranks in the 5th percentile.
KALV Stock Summary
- The ratio of debt to operating expenses for KalVista Pharmaceuticals Inc is higher than it is for about only 6.51% of US stocks.
- KALV's price/sales ratio is 143.41; that's higher than the P/S ratio of 97.06% of US stocks.
- Revenue growth over the past 12 months for KalVista Pharmaceuticals Inc comes in at -67.57%, a number that bests just 3.89% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to KalVista Pharmaceuticals Inc are GSIT, CERC, MRUS, AUTL, and RNA.
- Visit KALV's SEC page to see the company's official filings. To visit the company's web site, go to www.kalvista.com.
KALV Valuation Summary
- In comparison to the median Healthcare stock, KALV's price/earnings ratio is 151.88% lower, now standing at -17.9.
- KALV's price/earnings ratio has moved down 8.2 over the prior 76 months.
- Over the past 76 months, KALV's EV/EBIT ratio has gone down 6.8.
Below are key valuation metrics over time for KALV.
KALV Stock Price Chart Interactive Chart >
KALV Price/Volume Stats
|Current price||$19.38||52-week high||$45.00|
|Prev. close||$19.25||52-week low||$12.01|
|Day high||$19.39||Avg. volume||520,034|
|50-day MA||$20.41||Dividend yield||N/A|
|200-day MA||$23.83||Market Cap||473.61M|
KalVista Pharmaceuticals, Inc. (KALV) Company Bio
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The companys product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.
Most Popular Stories View All
KALV Latest News Stream
|Loading, please wait...|
KALV Latest Social Stream
View Full KALV Social Stream
Latest KALV News From Around the Web
Below are the latest news stories about KalVista Pharmaceuticals Inc that investors may wish to consider to help them evaluate KALV as an investment opportunity.
CAMBRIDGE, Mass. & SALISBURY, England, September 09, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2021.
CAMBRIDGE, Mass. & SALISBURY, England, September 02, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on September 1, 2021 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England, August 23, 2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema (HAE).
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista''s board of directors granted four newly-hired employees inducement options to purchase an
No summary available.
KALV Price Returns
Continue Researching KALVWant to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:
KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch